Company Overview
| Stock Name | 藥明生物技術有限公司 |
|---|---|
| Stock Code | 02269 |
| Company Full Name | 藥明生物技術有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要提供有關生物制劑藥物發現、開發與生產服務。 |
| Listing Date | 2017-06-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市外高橋自貿區富特中路288號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.wuxibiologics.com.cn |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 20.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,192,637,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 28.25 |
|---|---|
| First Day Open | HK$ 25.0 |
| First Day Change | 37.14% |
| First Day Volume | 143609000.0 |
| First Day Turnover | 3805510000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45.1%或1,428.3百萬港元，將用于償還我們全部未清償銀行融資； 2、約44.9%或1,420.3百萬港元，將用于建造新設施及設施改進及維護； 3、約10%或316.5百萬港元，將用于我們的營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198
摩根士丹利亚洲有限公司 CE AAD291
招商证券（香港）有限公司 CE AAI650
Overall Coordinators (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198
摩根士丹利亚洲有限公司 CE AAD291
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198
摩根士丹利亚洲有限公司 CE AAD291
招商证券（香港）有限公司 CE AAI650
Joint Lead Managers (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198
摩根士丹利亚洲有限公司 CE AAD291
招商证券（香港）有限公司 CE AAI650
HEAD & SHOULDERS SECURITIES LIMITED CE AFS455
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 李革 |
|---|---|
| Company Secretary | 黃躍;岑影文 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | WuXi Biologics Holdings Limited(15.02%);J.P. Morgan Chase & Co.(9.89%);The Capital Group Companies, Inc.(7.10%);貝萊德(5.99%) |
|---|
